Please login to order a test.
14.3.3 eta, Rheumatoid Arthritis
- 14.3.3η Protein ETA
Expected Turnaround Time
6 - 12 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
For more information, please view the literature below.
0.5 mL (Note: This volume does not allow for repeat testing).
Red-top tube or gel-barrier tube
Serum must be separated from cells within 45 minutes of venipuncture. Send serum in a plastic transfer tube.
Refrigerate. Stable at room temperature or refrigerated for three days. Frozen for seven days. Freeze/thaw cycles x6.
Causes for Rejection
14-3-3 eta protein is a joint-derived, proinflammatory mediator that is implicated in the joint erosion process and pathogenesis of RA. Serum 14-3-3 eta is elevated in both early and established RA.
This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).
Enzyme-linked immunosorbent assay (ELISA)
14-3-3 eta is highly specific for RA. Serum 14-3-3 eta may be especially helpful in identifying patients with early RA where it provides a 15% incremental benefit to the diagnostic sensitivity of markers, Rheumatoid Arthritis (RA) Factor and Cyclic Citrullinated Peptide (CCP) Antibodies.1 See table.
Diagnostic sensitivity: Complementarity between diagnostic markers (14-3-3η, RF and anti-CCP) in patients with early and established RA. Table 3A2
RF: rheumatoid factor, anti-CCP: anticitrullinated protein antibodies, RA: rheumatoid arthritis
Anti-CCP and RF+
14-3-3η+ and RF+
14-3-3η+ and anti-CCP+
14-3-3η+ and RF+ and anti-CCP+
Positive serum 14-3-3 eta levels are associated with higher rates of joint damage as measured by radiographic assessments (Sharp/van der Heijde Score).3